Minimal residual disease as the target for immunotherapy of cancer
- 14 May 1994
- journal article
- Published by Elsevier in The Lancet
- Vol. 343 (8907), 1172-1174
- https://doi.org/10.1016/s0140-6736(94)92394-9
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapyBlood, 1993
- Editorial overview Tumor immunology: present perspectivesCurrent Opinion in Immunology, 1993
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapyInternational Journal of Cancer, 1993
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 1992
- Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.Journal of Clinical Oncology, 1990